All In MedTech

Device Trial Radar · NCT07700043

Noise Reduction With Hearing Aids

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Sep 2029

Study completion Sep 2029

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD)
First posted
Jul 13, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to use an optimized version of the SEDA algorithm (SEDA-HA) for hearing aids to evaluate the benefit for listeners with varying degrees of hearing loss in realistic environments and evaluate its impact on speech perception and sound quality. The primary objective is to evaluate performance with and without the SEDA-HA algorithm on speech perception and speech reception tasks. The secondary objective is to evaluate performance of and experience with SEDA-HA integrated into a portable hearing aid prototype in the laboratory and in real-world situations outside the laboratory.

Conditions

  • Bilateral Sensorineural Hearing Loss

Interventions

  • Speech Enhancement using Decomposition Approach-Hearing Aid (SEDA-HA) algorithmDevice

    All participants will complete the testing using the SEDA-HA algorithm.

  • Hearing aid (HA) prototype with SEDA-HA algorithmDevice

    The study device is a non-invasive, acoustic hearing aid prototype developed by York Sound. Participants ages 18 and older will then take-home the HA prototype to begin the at home protocol for 30 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of words repeated with SEDATime frame: Day 1 (up to 4 hours)
  2. Number of words repeated without SEDATime frame: Day 1 (up to 4 hours)
  3. Number of participants who preferred SEDA-on conditionTime frame: Day 30

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.